Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMA ADMA Biologics	$18.08 +0.5%	$19.48	$10.21 ▼ $25.67	$4.32B	0.43	3.66 million shs	102,065 shs
AKRO Akero Therapeutics	$52.56 +1.5%	$49.94	$21.34 ▼ $58.40	$4.19B	-0.15	1.05 million shs	35,920 shs
CDTX Cidara Therapeutics	$51.68 +0.3%	$31.92	$10.14 ▼ $56.83	$1.04B	1.14	203,595 shs	28,798 shs
KRYS Krystal Biotech	$149.69 +1.3%	$135.75	$122.80 ▼ $219.34	$4.33B	0.67	286,576 shs	36,901 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMA ADMA Biologics	-3.75%	+0.95%	-13.60%	-15.31%	+34.28%
AKRO Akero Therapeutics	-1.84%	+2.76%	-6.94%	+38.25%	+88.56%
CDTX Cidara Therapeutics	-6.92%	+2.06%	+125.44%	+168.46%	+311.92%
KRYS Krystal Biotech	-1.78%	+3.06%	+7.78%	-10.30%	-28.93%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADMA ADMA Biologics	3.8644 of 5 stars	3.7	1.0	0.0	2.9	2.5	3.1
AKRO Akero Therapeutics	3.518 of 5 stars	3.5	1.0	4.7	2.1	0.8	0.0
CDTX Cidara Therapeutics	4.1779 of 5 stars	3.6	2.0	4.6	3.9	1.7	0.0
KRYS Krystal Biotech	4.6302 of 5 stars	3.5	1.0	4.7	2.9	3.3	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMA ADMA Biologics	3.33	Buy	$27.67	53.07% Upside
AKRO Akero Therapeutics	3.00	Buy	$82.50	56.96% Upside
CDTX Cidara Therapeutics	3.11	Buy	$57.29	10.86% Upside
KRYS Krystal Biotech	3.00	Buy	$213.75	42.80% Upside

Current Analyst Ratings Breakdown

Latest CDTX, ADMA, KRYS, and AKRO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/9/2025	KRYS Krystal Biotech	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$155.00 ➝ $176.00
7/9/2025	CDTX Cidara Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$69.00
6/30/2025	CDTX Cidara Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$59.00
6/24/2025	CDTX Cidara Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/24/2025	CDTX Cidara Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$35.00 ➝ $75.00
6/24/2025	CDTX Cidara Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$50.00 ➝ $68.00
6/24/2025	KRYS Krystal Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$240.00
6/23/2025	CDTX Cidara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$41.00 ➝ $53.00
6/23/2025	CDTX Cidara Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$36.00 ➝ $54.00
6/23/2025	CDTX Cidara Therapeutics	WBB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Strong-Buy ➝ Strong-Buy	$45.00
6/18/2025	CDTX Cidara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$41.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMA ADMA Biologics	$426.45M	10.12	$0.52 per share	34.51	$1.48 per share	12.21
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	$10.75 per share	N/A
CDTX Cidara Therapeutics	$302K	3,450.25	N/A	N/A	$14.92 per share	3.46
KRYS Krystal Biotech	$333.45M	12.97	$4.62 per share	32.43	$32.90 per share	4.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMA ADMA Biologics	$197.67M	$0.85	21.31	26.20	N/A	45.01%	47.16%	30.51%	8/6/2025 (Estimated)
AKRO Akero Therapeutics	-$252.06M	-$1.95	N/A	N/A	N/A	N/A	-15.19%	-13.97%	8/8/2025 (Estimated)
CDTX Cidara Therapeutics	-$169.83M	-$29.47	N/A	N/A	N/A	N/A	-73.04%	-54.28%	8/12/2025 (Estimated)
KRYS Krystal Biotech	$89.16M	$4.16	36.00	14.85	N/A	37.17%	14.64%	13.28%	8/4/2025 (Estimated)

Latest CDTX, ADMA, KRYS, and AKRO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	CDTX Cidara Therapeutics	-$1.87	N/A	N/A	N/A	N/A	N/A
8/8/2025	Q2 2025	AKRO Akero Therapeutics	-$0.95	N/A	N/A	N/A	N/A	N/A
8/4/2025	Q2 2025	KRYS Krystal Biotech	$1.20	N/A	N/A	N/A	$95.42 million	N/A
5/12/2025	Q1 2025	AKRO Akero Therapeutics	-$1.01	$0.90	+$1.91	$0.90	N/A	N/A
5/8/2025	Q1 2025	CDTX Cidara Therapeutics	-$5.45	-$1.66	+$3.79	-$1.66	N/A	N/A
5/7/2025	Q1 2025	ADMA ADMA Biologics	$0.16	$0.14	-$0.02	$0.11	$116.40 million	$114.80 million
5/6/2025	Q1 2025	KRYS Krystal Biotech	$1.38	$1.20	-$0.18	$1.20	$98.66 million	$88.18 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMA ADMA Biologics	N/A	N/A	N/A	N/A	N/A
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	N/A
CDTX Cidara Therapeutics	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMA ADMA Biologics	0.22	6.58	3.36
AKRO Akero Therapeutics	0.03	16.80	16.80
CDTX Cidara Therapeutics	N/A	3.87	3.87
KRYS Krystal Biotech	N/A	9.65	9.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADMA ADMA Biologics	75.68%
AKRO Akero Therapeutics	N/A
CDTX Cidara Therapeutics	35.82%
KRYS Krystal Biotech	86.29%

Insider Ownership

Company	Insider Ownership
ADMA ADMA Biologics	3.70%
AKRO Akero Therapeutics	7.07%
CDTX Cidara Therapeutics	7.64%
KRYS Krystal Biotech	13.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMA ADMA Biologics	530	238.73 million	229.90 million	Optionable
AKRO Akero Therapeutics	30	79.72 million	74.08 million	Optionable
CDTX Cidara Therapeutics	90	20.16 million	18.62 million	No Data
KRYS Krystal Biotech	210	28.90 million	24.94 million	Optionable

CDTX, ADMA, KRYS, and AKRO Headlines

Recent News About These Companies

Segall Bryant & Hamill LLC Lowers Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

3 hours ago | marketbeat.com

Analysts Set Expectations for Krystal Biotech Q2 Earnings

5 hours ago | marketbeat.com

M&T Bank Corp Purchases New Shares in Krystal Biotech, Inc. (NASDAQ:KRYS)

July 16 at 3:49 AM | marketbeat.com

William Blair Lowers Earnings Estimates for Krystal Biotech

July 15 at 7:48 AM | marketbeat.com

Krystal Biotech doses first patient in EMERALD-1 phase 1/2 trial for neurotrophic keratitis

July 14 at 11:49 AM | ophthalmologytimes.comO

Krystal Biotech, Inc. (NASDAQ:KRYS) Holdings Cut by TimesSquare Capital Management LLC

July 14 at 8:54 AM | marketbeat.com

William Blair Forecasts Lower Earnings for Krystal Biotech

July 14 at 2:39 AM | marketbeat.com

William Blair Reduces Earnings Estimates for Krystal Biotech

July 13 at 2:17 AM | americanbankingnews.com

Suma Krishnan Sells 200 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) Stock

July 12, 2025 | insidertrades.com

Insider Selling: Krystal Biotech, Inc. (NASDAQ:KRYS) Insider Sells 200 Shares of Stock

July 11, 2025 | marketbeat.com

Insider Selling: Krystal Biotech, Inc. (NASDAQ:KRYS) Insider Sells 6,927 Shares of Stock

July 11, 2025 | marketbeat.com

Citi raises Krystal Biotech stock price target to $176 on KB801 trial ...

July 11, 2025 | investing.com

Q2 EPS Estimates for Krystal Biotech Decreased by Analyst

July 11, 2025 | marketbeat.com

KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up

July 10, 2025 | zacks.com

Principal Financial Group Inc. Has $22.78 Million Stake in Krystal Biotech, Inc. (NASDAQ:KRYS)

July 10, 2025 | marketbeat.com

Pittsburgh tech's future isn't guaranteed, CEO warns

July 9, 2025 | msn.com

Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis

July 9, 2025 | globenewswire.com

Allspring Global Investments Holdings LLC Decreases Stake in Krystal Biotech, Inc. (NASDAQ:KRYS)

July 9, 2025 | marketbeat.com

High Insider Ownership In 3 Promising Growth Companies

July 8, 2025 | finance.yahoo.com

Krystal Biotech Inc. Research & Ratings | KRYS - Barron's

July 3, 2025 | barrons.com

Krystal Biotech, Inc.'s (NASDAQ:KRYS) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

July 3, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains
By Nathan Reiff | June 30, 2025
View Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains

CDTX, ADMA, KRYS, and AKRO Company Descriptions

ADMA Biologics NASDAQ:ADMA

$18.08 +0.10 (+0.53%)

As of 10:28 AM Eastern

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Akero Therapeutics NASDAQ:AKRO

$52.56 +0.80 (+1.55%)

As of 10:28 AM Eastern

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Cidara Therapeutics NASDAQ:CDTX

$51.68 +0.18 (+0.34%)

As of 10:28 AM Eastern

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Krystal Biotech NASDAQ:KRYS

$149.68 +1.96 (+1.32%)

As of 10:28 AM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time